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P R E V I E W S
The beginning of the 21st century has
brought the hope and expectation that an
emerging understanding of the human
genome will bring about a transformation
of the practice of medicine. In the field of
cancer, it now becomes likely that over the
next decade or two, it will become possi-
ble to classify all cancers on the basis of
their underlying genetics and physiology.
These goals are being largely addressed
through the use of DNA microarrays for
monitoring the RNA profiles of tumor
specimens. Significant progress has been
made in many areas including breast can-
cer (van de Vijver et al., 2002), lymphoma
(Rosenwald et al., 2002), and most
recently, acute myeloid leukemia (AML)
(Bullinger et al., 2004; Valk et al., 2004),
among others. A molecular taxonomy of
cancer thus appears feasible.
Yet, RNA profiles of tumor biopsies
or resected specimens cannot possibly
capture all of the relevant molecular
detail of a given cancer. For one, much of
cellular behavior is governed by transla-
tional and posttranslational control
mechanisms that are not reflected in
RNA profiles.This has led some to argue
that a definitive molecular classification
of cancer would require proteomic analy-
sis.While this may be correct in principle,
the ability to perform high-throughput,
detailed proteomic analysis of tumors is
at least several years off. As such, RNA
profiling still represents the most
tractable, high information content, high-
throughput classification platform.
Far more important than the RNA ver-
sus protein debate is the fact that molecu-
lar analysis of tumors creates a snapshot
of the biological state of the tissue at the
time of biopsy. Differences in dynamic
response to environmental conditions
(e.g., growth factor stimulation, microenvi-
ronmental effects) are not exposed. That
is, the resting profiles of two tumors could
be the same, yet their response to
provocation entirely different—and highly
relevant to understanding the clinical
behavior of human cancers.
This notion of classifying cancers
according to their dynamic response to
perturbation is explored for the first time
in an important paper by Garry Nolan and
colleagues in the July 23 issue of Cell
(Irish et al., 2004). In this work, the
authors use flow cytometry of leukemic
cells to assess the phosphorylation state
of 6 signaling proteins (Stat1, Stat3,
Stat5, Stat6, p38, and Erk1/2) in
response to 5 cytokine perturbations
(FLT3 ligand, GM-CSF, G-CSF, IL-3, and
interferon γ). The experiments were first
conducted in leukemic cell lines, and then
extended to primary blasts from patients
with AML. The studies show quite con-
vincingly that the phosphorylation status
of signaling proteins at baseline is not
predictive of their response to cytokine
stimulation. For example, Stat5, known to
be a downstream effector of the receptor
tyrosine kinase FLT3, exhibited equiva-
lent phosphorylation in FLT3 wild-type
versus mutant (resulting in constitutive
FLT3 activity) AMLs. However, Stat5
phosphorylation in response to cytokine
stimulation differed significantly between
FLT3 wild-type and mutant leukemias. In
fact, FLT3 status could be predicted
based on Stat5 (and other Stat proteins)
response to cytokine treatment. Along
those same lines, clustering of these
dynamic responses led to successful pre-
diction of response to chemotherapy.
This paper is noteworthy for several
reasons. First and foremost, it demon-
strates the feasibility of classifying tumors
(or in fact any cell) on the basis of their
response to cellular perturbation, thereby
exposing a new dimension of cellular
activity not otherwise accessible. Second,
the study demonstrates the power of
phospho-proteomic analysis, where sin-
gle cell phosphorylation status is exam-
ined. Standard flow cytometry is
reinvented as “single cell profiling” in
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Interrogating the genomes of tumor cells with genomic and proteomic methods is becoming a mainstay of modern cancer
classification efforts. This notion is brought to a new level by a paper in the July 23 issue of Cell, in which the dynamic
responses of leukemia cells to perturbation are cataloged by flow cytometry, and the leukemias classified in terms of their
functional responses.This study paves the way for more systematic attempts to bring functional genomics to the study of
human cancer.
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keeping with current enthusiasm around
proteomics technologies. But perhaps this
new spin will reawaken flow cytometry’s
proven record as a robust means of quan-
titatively assessing protein expression at
the individual cell level. Third, the authors
demonstrate that this approach can be
taken not only with established cell lines,
but also with primary leukemic blasts.
Indeed, a significant amount of hetero-
geneity in cellular response was observed
within individual patient samples.Whether
this heterogeneity will prove to be clinical-
ly important remains to be determined.
To be sure, the study is limited by the
small numbers of analytes (e.g., Stat
proteins) and small number of perturba-
tions (cytokine stimulations). But, the
proof of principle is established that clas-
sification based on dynamic response to
perturbation is feasible and informative.
As higher complexity proteomic profiling
methods are established, they should be
able to be utilized within this same con-
ceptual framework. Less clear is whether
or not specific new insights into signal
transduction in leukemia were garnered
by this study. Similarly, the sparseness of
the data makes it difficult to form a true
network understanding of signaling in
these cells.
Nevertheless, the study does raise
the provocative notion that a functional
taxonomy of cancer—that is, a taxonomy
built on functional response (however
measured) to a diverse set of cellular per-
turbations—could be highly informative.
Of course there are at present numerous
technical limitations to the widespread
application of this approach to solid
tumors, but the principle is indeed estab-
lished, and the study will hopefully prompt
others to use the tools of genomics and
high dimensionality data analysis and
bring them to bear on studying the func-
tional consequences of perturbation of
cancer cells. Such efforts will at last put
the functional in functional genomics.
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P R E V I E W S
Imatinib, a selective inhibitor of the ABL
tyrosine kinase, is a highly effective
treatment for chronic myeloid leukemia
(CML), a disease driven by the activated
BCR-ABL tyrosine kinase. Relapses
after an initial response have occurred in
a small percentage of chronic phase
patients, but are quite common in
patients with advanced disease. In the
majority of cases, resistance is caused
by reactivation of BCR-ABL kinase activ-
ity, indicating that resistance could be
overcome if inhibition of BCR-ABL was
restored. After the original report of a
threonine to isoleucine substitution at
amino acid 315 (T315I) (Gorre et al.,
2001), it has become clear that muta-
tions in the kinase domain of BCR-ABL
are the predominant mechanism under-
lying acquired drug resistance, although
some patients have amplification of
BCR-ABL (Hochhaus et al., 2002; Shah
et al., 2002). Mutations have now been
observed in at least 17 different amino
acids scattered throughout the ABL
kinase domain and render the kinase
variably less sensitive to imatinib (Shah
et al., 2002; Corbin et al., 2003).
Once it became clear that resistance
to imatinib was frequently due to muta-
tions of BCR-ABL, alternative inhibitors
that could inhibit these ABL mutants
were sought. The first compound identi-
fied with this capability, PD180970, a
pyridopyrimidine derivative, had original-
ly been developed as a SRC kinase
inhibitor, but was subsequently shown to
inhibit wild-type ABL at nanomolar con-
centrations (Dorsey et al., 2000). Based
on structural data discussed later, we
reasoned that SRC/ABL inhibitors would
likely inhibit the kinase domain mutants
detected in patients and showed, with
the notable exception of T315I, that
PD180970 inhibited all imatinib-resistant
BCR-ABL kinase domain mutants tested
in vitro (La Rosee et al., 2002). Although
the unfavorable pharmacokinetic profile
of the pyridopyrimidine derivatives pre-
cluded their clinical development, these
studies provided proof of principle for the
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The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial
response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism dri-
ving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations,
and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mecha-
nism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These
studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.
